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Nicastrin regulates g-secretase cleavage of the amyloid precursor protein by forming complexes with presenilins,
in which most mutations causing familial early-onset Alzheimer disease (EOAD) have been found. The gene encoding
nicastrin (NCSTN) maps to 1q23, a region that has been linked and associated with late-onset Alzheimer disease
(LOAD) in various genome screens. In 78 familial EOAD cases, we found 14 NCSTN single-nucleotide polymor-
phisms (SNPs): 10 intronic SNPs, 3 silent mutations, and 1 missense mutation (N417Y). N417Y is unlikely to be
pathogenic, since it did not alter amyloid b secretion in an in vitro assay and its frequency was similar in case and
control subjects. However, SNP haplotype estimation in two population-based series of Dutch patients with EOAD
( ) and LOAD ( ) indicated that the frequency of one SNP haplotype (HapB) was higher in thenp 116 np 240
group with familial EOAD (7%), compared with the LOAD group (3%) and control group (3%). In patients with
familial EOAD without the APOE e4 allele, the HapB frequency further increased, to 14%, resulting in a fourfold
increased risk (odds ratio p 4.1; 95% confidence interval 1.2–13.3; ). These results are compatible withPp .01
an important role of g-secretase dysfunction in the etiology of familial EOAD.
The amyloid b peptide (Ab) is the main component of
the neuritic plaque, the histological hallmark lesion in
the brains of patients with Alzheimer disease (AD [MIM
104300]). Ab is generated by b- and subsequent g-se-
cretase cleavage of the amyloid precursor protein (APP
[MIM 104760]). Mutations in APP and the presenilins
(PSEN1 [MIM 104311] and PSEN2 [MIM 600759])
cause the rare familial early-onset type of AD (EOAD)
(AD Mutation Database). Since the large majority of
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causative EOADmutations directly influence g-secretase
activity, at the level of either the substrate (APP muta-
tions at the g cleavage site) or the enzyme (all PSEN
mutations), g-secretase dysfunction is crucial in familial
EOAD pathogenesis. Recent findings by us (van Duijn
et al. 1999; Theuns et al. 2000) and others (Lambert et
al. 2001), of genetic association between the promot-
er region of PSEN1 and EOAD, further emphasize the
importance of altered g-secretase activity in EOAD.
Recently, a novel type 1 transmembrane glycoprotein,
designated “nicastrin” (NCSTN [MIM 605254]), was
identified as a component of the presenilin-containing
g-secretase complex that is involved in the cleaving of
APP and Notch in their transmembrane domains (Yu et
al. 2000; Chen et al. 2001). Like all pathogenic PSEN
mutations, missense mutations in a conserved hydro-
philic domain (DYIGSrAAIGS) in NCSTN strongly in-
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Figure 1 Genomic structure of NCSTN and major SNP haplotypes, with their estimated frequencies in 78 patients with familial EOAD.
SNPs used for case-control association analysis are in boldface.
creased Ab production, whereas deletions in this domain
inhibited Ab production (Yu et al. 2000). NCSTN maps
to 1q23, a region that has shown evidence for linkage
to (Kehoe et al. 1999) and association with LOAD (Hil-
tunen et al. 2001).
We evaluated the contribution of genetic variations in
NCSTN in two large series of patients with EOAD (onset
before or at age 65 years) and LOAD (onset after age
65 years). Patients with EOAD were derived from a
Dutch population-based study of EOAD in the four
northern provinces of the Netherlands and metropolitan
Rotterdam (van Duijn et al. 1994a). The patients were
sampled during two study periods. The original sample
was collected between 1980 and 1987 and has been
described elsewhere (van Duijn et al. 1994b). The initial
study was extended between 1997 and 2000, in a ge-
netically isolated part of the previously described area,
with the same sampling criteria. The current sample
comprises 96 patients from the original group, with an
additional 20 patients from the extended study. Mean
age at onset was years, and 23% of patients56.4 5.5
in the sample were male. The diagnosis was indepen-
dently confirmed by a member of the research team and
by a neurologist using a standardized protocol consistent
with the National Institute of Neurological and Com-
municative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA)
criteria for AD (McKhann et al. 1984). The disease in
38 patients was classified as sporadic, and the disease
in 78 patients was classified as familial (i.e., at least one
first-degree relative with dementia), 10 cases of which
fulfilled our criteria of autosomal dominant inheritance
(Cruts et al. 1998). In this sample, seven patients were
identified who carried a causative PSEN mutation (five
in PSEN1 and two in PSEN2) (Cruts et al. 1998; authors’
unpublished data). Patients with EOAD were compared
with a control group of 114 individuals in the same age
range (mean age at examination years; 46%60.6 3.3
male). Patients with LOAD were drawn from the Rot-
terdam study, a population-based prospective study on
residents of age 55 years from a Rotterdam suburb in
the Netherlands (Hofman et al. 1991). Dementia was
diagnosed by a three-step examination, as detailed else-
where (Ott et al. 1995). The diagnosis of probable AD
was based on NINCDS-ADRDA criteria (McKhann et
al. 1984): 339 patients with AD were ascertained at the
start of the study, and 116 patients with incident AD
were diagnosed at the first follow-up period. DNA was
available for 240 patients with probable LOAD cases
(mean age at onset years; 20% male). Pa-84.1 6.9
tients with LOAD were compared to 239 control indi-
viduals (mean age at examination years;72.1 3.7
15% male). All control individuals were taken from the
Rotterdam study and were screened for cognitive dys-
function. Potential control subjects with dementia were
excluded.
We determined the genomic organization of NCSTN
(gDNA: 15.9 kb; cDNA: 2.9 kb) by alignment of the
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Table 1
NCSTN Sequence Variations and Their Allele Frequencies in 78
Familial EOAD Cases
Location Polymorphism
No. (Frequency)
of Mutant Allelea
Exon 3 c.237GrA (Glu79) 2 (.01)
Intron 4 IVS469CrG 1 (.01)
Intron 5 IVS574CrT 13 (.08)
Exon 6 c.636ArG (Leu212) 13 (.08)
Intron 6 IVS618CrG 8 (.05)
Exon 7 c.747CrT (Asp249) 13 (.08)
Intron 7 IVS761GrA 2 (.01)
Intron 10 IVS1032CrG 1 (.01)
Intron 10 IVS105CrG 13 (.08)
Exon 11 c.1249ArT (Asn417Tyr) 1 (.01)
Intron 13 IVS13129TrC 16 (.10)
Intron 15 IVS1531insG 1 (.01)
Intron 16 IVS16119GrC 16 (.10)
Intron 16 IVS1674CrT 3 (.02)
a Frequencies are given as proportion of total alleles.Np 156
complete cDNA sequence (NCSTN cDNA [GenBank
accession number AF240468]) against the human work-
ing draft sequence (Human Genome Project Work-
ing Draft Web site). NCSTN consists of 17 exons (fig.
1), all of which contain coding sequence. Using PCR
primers flanking each exon, we screened NCSTN exons
1–16 and the coding part of exon 17 by denaturing high-
performance liquid chromatography (DHPLC) in 78 pa-
tients with familial AD, including 10 patients with au-
tosomal dominant EOAD. Direct sequencing of PCR
fragments with aberrant DHPLC patterns revealed 14
single nucleotide polymorphisms (SNPs), of which 10
were located in introns and 4 in coding regions (table
1). Direct sequencing of NCSTN in the probands of the
10 autosomal dominant families revealed no causative
mutations or additional variations. Only c.1249ArT
predicts an amino acid substitution (NrY at codon 417)
and was found in a patient with familial EOAD (age at
onset 57 years). No other family members were available
for segregation analysis. NCSTN N417Y is a conser-
vative amino acid substitution affecting a residue that is
not evolutionarily conserved in mouse (A), Drosophila
(E), or Caenorhabditis elegans (G) (Yu et al. 2000) but
is located within a putative glycosylation site (N-Q-S).
To test the potential contribution of N417Y to AD, we
used a pyrosequencing assay (Alderborn et al. 2000;
Theuns et al. 2001) to screen all patients with EOAD,
as well as 235 patients with probable LOAD and a total
of 474 control subjects taken from the Rotterdam study.
In addition to the patient with familial EOAD, N417Y
was also found in one patient with LOAD (familial; age
at onset 87 years) and in three control subjects without
dementia (ages 84, 87, and 95 years), resulting in iden-
tical N417Y carrier frequencies in patients with AD
( ) and controls ( ). To as-2/354p 0.6% 3/474p 0.6%
sess whether NCSTNN417Y influences APP processing,
we measured Ab40 and Ab42 levels in conditioned me-
dia of HEK-293 cells transfected with the mutant and
wild-type NCSTN cDNA. Results were compared with
PSEN1 L392V, a clinical mutation causing familial
EOAD that is known to increase Ab42 levels (Sherring-
ton et al. 1995; Citron et al. 1997), and PSEN1 D385A,
an artificial mutation that substantially reduces Ab pro-
duction (Wolfe et al. 1999). Although both PSEN1 mu-
tations showed the expected effects on Ab production,
Ab40 and Ab42 levels were similar for N417Y and wild-
type NCSTN (data not shown).
To further evaluate the possibility that variations in
NCSTN affect susceptibility to EOAD or LOAD, case-
control association analysis was performed. Because of
strong linkage disequilibrium between the SNPs in the
78 familial EOAD samples, we selected four informative
SNPs (c.636ArG, IVS618CrG, IVS105CrG, and
IVS16119GrC) that allowed definition of four ma-
jor haplotypes: A, B, C, and D (hereafter referred to
as “HapA,” “HapB,” “HapC,” and “HapD”) (fig. 1).
Through use of a pyrosequencing assay, genotypes for
each of these four SNPs were determined in patients
with EOAD, patients with LOAD, and with their age-
matched control groups (table 2). Genotype frequencies
for each SNP were in Hardy-Weinberg equilibrium
(HWE) in all case and control groups ( ). No sta-P 1 .23
tistically significant differences in genotype frequencies
were observed between patients with EOAD and LOAD
and control subjects, at any of the four SNP loci tested.
We then estimated four-locus haplotype frequencies
from genotype data with a maximum-likelihoodmethod
using the expectation-maximization algorithm under the
assumption of HWE (Excoffier and Slatkin 1995). Es-
timated haplotype distributions in the different groups
were compared using CLUMP (Sham and Curtis 1995).
CLUMP generates empirical P values that are based on
Monte Carlo simulations and is useful for case-control
comparisons of multiallelic genetic markers. To test for
interaction between NCSTN and APOE, the case and
control series were stratified for the presence of an APOE
e4 allele. Haplotypes were estimated separately in the
patients with familial EOAD. Because haplotype fre-
quencies were not statistically different between the two
control groups ( ), and in order to obtain reliablePp .48
haplotype frequency estimates in the different APOE
strata, both control groups were pooled. In all groups
studied, haplotype estimation revealed one frequent
haplotype (HapA) and three rarer haplotypes (HapB,
HapC, and HapD) (table 3). We found no significant
differences in NCSTN haplotype distributions between
patients with LOAD and control subjects (table 3).
Moreover, haplotype frequencies remained highly stable
across APOE strata in both the LOAD and control
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Table 2
Genotype Frequencies of Four Selected NCSTN SNPs in Patients with EOAD, Patients with LOAD, and Control
Subjects
SNP AND
GENOTYPE
EOAD VERSUS CONTROL GROUP LOAD VERSUS CONTROL GROUP
No. (Frequency) in
P a
No. (Frequency) in
P aEOAD Group Control Group LOAD Group Control Group
c.636ArG:
AA 103 (.89) 102 (.89)
.87
220 (.94) 175 (.93)
.85AG 13 (.11) 12 (.11) 14 (.06) 12 (.07)
Total 116 114 234 187
IVS618CrG:
CC 108 (.93) 102 (.89)
.33
217 (.92) 198 (.91)
.90CGGG 8 (.07) 12 (.11) 20 (.08) 19b (.09)
Total 116 114 237 217
IVS105CrG:
CC 102 (.88) 102 (.89)
.71
215 (.92) 219 (.94)
.48CG 14 (.12) 12 (.11) 19 (.08) 15 (.06)
Total 116 114 234 234
IVS16119GrC:
GG 99 (.85) 97 (.85)
.96
188 (.88) 167 (.92)
.15GCCC 17 (.15) 17 (.15) 26c (.12) 14 (.08)
Total 116 114 214 181
a Calculated using the x2 statistic with 1 df.
b Includes one subject with the GG genotype.
c Includes two subjects with the CC genotype.
groups, suggesting no interaction between NCSTN and
APOE in the risk to develop LOAD. In the patients with
EOAD, however, we found an increased frequency of
HapB in those with familial EOAD (7%) and APOE
e4() EOAD (7%), compared with patients with LOAD
(3%) and control subjects (3%). In patients with familial
EOAD without APOE e4 alleles, the HapB frequency
further increased, to 14%, resulting in a significantly
different haplotype distribution ( ). When cal-Pp .01
culating risks by comparing the HapB frequencies in case
subjects and their age-matched control subjects and by
using the non-HapB haplotypes as reference, we found
that the HapB frequency was significantly increased in
patients with familial EOAD without APOE e4 alleles
(odds ratio [OR] 4.1; 95% CI 1.2–13.3; ). NoPp .01
homozygotes for HapB were observed. Assuming that
individuals heterozygous at c.636ArG, IVS105CrG,
and IVS16119GrC are heterozygous HapB carriers,
we found a significantly increased HapB/Hap* (where
Hap* is any non-HapB haplotype) genotype frequency
in patients with familial APOE e4() EOAD (33%),
compared with age-matched APOE e4() control sub-
jects (9%) (OR 4.9, 95% CI 1.5–16.3; ). SincePp .005
none of the apparent HapB carriers with EOAD had a
PSEN mutation, the exclusion of the seven PSEN mu-
tation carriers did not alter these results.
In the present study, we have investigated the contri-
bution of genetic variations in NCSTN to the occurrence
of AD, through use of a combined strategy of extensive
mutation screening in patients with familial EOAD and
subsequent case-control association analysis using four
NCSTN polymorphisms in large population-based series
of EOAD and LOAD. Although screening of all NCSTN
coding exons and flanking intronic sequences in 78 pa-
tients with familial EOAD revealed a total of 14 NCSTN
sequence variations, onlyNCSTNN417Y, detected in one
patient with familial EOAD, was potentially pathogenic.
However, its equal frequency in AD cases and controls
(allele frequency 0.3%), its inability to alter Ab produc-
tion in an in vitro assay, and its low evolutionary con-
servation in different species strongly suggest that N417Y
is a very rare but nonpathogenic variant. Although we
can therefore conclude that mutation of NCSTN is not
a frequent cause of EOAD, genetic association analy-
sis did reveal that the risk of developing familial EOAD
was modified by a significantly overrepresented NCSTN
haplotype (HapB) in patients with familial EOAD (7%),
particularly in those who lack APOE e4 alleles (14%),
compared with control subjects (3%) and patients with
LOAD (3%). Although we acknowledge the possibility
of a false-positive finding, from a biological point of view
the association between NCSTN and familial EOAD
seems highly plausible, for several reasons. First, the as-
sociation is caused by a specific overrepresentation of one
haplotype in patients and is not due to frequency shifts
in the control group, where NCSTN haplotypes remained
highly stable even when stratified for APOE. Second, it
is of interest that the most dramatic increase of HapBwas
1572 Am. J. Hum. Genet. 70:1568–1574, 2002
Table 3
Estimated NCSTN Four-Locus Haplotype Frequencies in Patients with EOAD, Patients with Familial EOAD,
Patients with LOAD, and Control Subjects, Stratified for the Presence of an APOE e4 Allele
SAMPLE AND
HAPLOTYPEa
CONTROL
GROUP
FREQUENCY
LOAD GROUP EOAD GROUP FAMILIAL EOAD GROUP
Frequency x2 P b Frequency x2 P b Frequency x2 P b
Total Sample:c
A (ACCG) .89 .89 .89 .85
B (GCGC) .03 .03 .05 .07
C (AGCG) .04 .04 1.1 .91 .03 2.3 .69 .05 7.8 .10
D (ACCC) .02 .02 .02 .02
Other .02 .02 .01 .01
APOE e4():d
A (ACCG) .92 .88 .92 .89
B (GCGC) .03 .01 .03 .05
C (AGCG) .04 .07 4.4 .35 .03 .1 1.00 .05 .4 .98
D (ACCC) .01 .01 .01 .01
Other .01 .03 .01 .01
APOE e4():e
A (ACCG) .89 .89 .82 .74
B (GCGC) .03 .03 .07 .14
C (AGCG) .04 .02 4.3 .37 .01 8.9 .06 .05 15.1 .01
D (ACCC) .02 .03 .05 .05
Other .02 .02 .04 .03
a Underlined bases are those that differ from the wild-type haplotype.
b Generated using CLUMP, by random simulation of 1,000 2#5 tables with the same marginal totals as the one
under consideration and by counting the number of times that a x2 value associated with the real table was achieved.
c Control group, ; LOAD group, ; EOAD group, ; familial EOAD group, .np 472 np 426 np 232 np 156
d Control group, ; LOAD group, ; EOAD group, ; familial EOAD group, .np 130 np 160 np 152 np 114
e Control group, ; LOAD group, ; EOAD group, ; familial EOAD group, .np 342 np 266 np 80 np 42
observed in patients with familial EOAD who lack all
well-established genetic factors (i.e., APOE e4 alleles and
PSEN or APP mutations), suggesting that the familial oc-
currence within this more homogeneous subgroup might
at least be partially attributed to the NCSTN locus. Our
results also suggest that an association in the total EOAD
group may have been masked by the high number of
APOE e4 carriers (65% of the sample), while the effect
is only present in non-e4 carriers. Third, our finding of
an effect in EOAD but not in LOAD is in line with our
previous studies showing an association of the PSEN1
regulatory region locus with EOAD (van Duijn et al.
1999; Theuns et al. 2000) but not LOAD (Dermaut et
al. 2001) and is consistent with the concept that an in-
creased production of Ab by altered g-secretase activity
is the primary pathogenetic event in (familial) EOAD. In
contrast, in LOAD, the relative importance of altered pro-
duction versus degradation or clearance of Ab is still a
matter of debate. Although independent replication stud-
ies are needed to further validate our findings, it is pres-
ently unclear what the underlying biological mechanism
of the association might be. Because we detected only
intronic or silent variations, we are currently screening
the upstream regulatory region of NCSTN, in order to
assess the possibility that an undetected variation in LD
with HapB that influences nicastrin expression levels
might explain our association. In addition, it cannot be
excluded that variations in a nearby gene in LD with
NCSTN HapB may be responsible for the observed as-
sociation. According to the human draft sequence data-
base, NCSTN is flanked by the gene encoding the a sub-
unit of the coatamer protein complex (COPA [MIM
601924]) at its 5′ side and by the gene encoding the nes-
cient helix loop helix 1 protein (NHLH1 [MIM 601924])
at the 3′ side. However, there is currently no direct evi-
dence that these genes are implicated in AD pathogenesis.
In conclusion, our data show that mutation of the
NCSTN coding region is not a frequent cause of EOAD
but suggest that a specific NCSTN haplotype modifies
the risk of developing familial EOAD, particularly in
those cases that lack an APOE e4 allele. Contrary to our
expectation that NCSTN might be responsible for the
reported positional evidence of an LOAD gene on 1q23,
variation in NCSTN does not confer risk of LOAD in
our sample.
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